Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2002, for Bioanalytical Systems, Inc. (BASi). The company provides laboratory services, consulting, and research related to analytical chemistry, as well as manufacturing scientific instruments for trace organic compound determination. The registrant operates in two principal segments: analytical services and analytical products.
Key Financial Metrics
| Metric | Q1 2003 (Ended Dec 31, 2002) | Q1 2002 (Ended Dec 31, 2001) |
|---|---|---|
| Total Revenue | $6,974,000 | $6,023,000 |
| Gross Profit | $2,685,000 | $2,556,000 |
| Operating Income | $469,000 | $437,000 |
| Net Income | $275,000 | $247,000 |
| Diluted EPS | $0.06 | $0.05 |
| Cash and Equivalents (End of Period) | $1,612,000 | $636,000 |
| Net Cash Used by Operating Activities | ($478,000) | $14,000 |
| Total Debt (Current + Long-Term) | $13,376,000 | Filing text does not provide a clear comparative total for Q1 2002 |
Note: Debt figures include revolving line of credit, construction loans, mortgage, capital leases, and subordinated debt.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 15.8% year-over-year, driven primarily by a 27% increase in service revenue ($4.53M vs $3.57M) due to increased contract activity.
- Cost Structure: Cost of revenue increased 23.7% to $4.29M. While service revenue costs improved as a percentage of revenue (71.8% vs 73.4%), product revenue costs rose to 42.3% from 34.5% due to product mix changes.
- Operating Expenses: Total operating expenses rose 5.0% to $2.22M, primarily due to increased staffing costs and a decrease in grant reimbursements affecting R&D expenses.
- Cash Flow: Operating cash flow turned negative ($478k used) compared to a slight positive ($14k provided) in the prior year, driven by a $551k increase in accounts receivable and a $418k decrease in accounts payable.
- Acquisition: BASi acquired LC Resources, Inc. (LCR) on December 13, 2002, for approximately $2.1M, adding $1.35M in goodwill.
Outlook, Risks, and Management Commentary
- Liquidity and Debt Covenants: Management is actively implementing a plan to reduce debt and improve cash flow to satisfy credit agreement covenants. This includes headcount reductions, cost-saving measures, and the sale of real estate assets.
- Construction Delays: Construction on the West Lafayette expansion project has been delayed to ensure compliance with debt covenants. Significant borrowings for this project are deferred until cash flow improves.
- PharmaKinetics (PKLB) Merger: BASi is pursuing a merger with PharmaKinetics Laboratories, Inc. This involves issuing approximately $4M in subordinated convertible notes. BASi intends to sell PKLB's Baltimore property to fund operations and pay down the line of credit. Management may defer the acquisition if necessary to maintain covenant compliance.
- Accounting Changes: BASi adopted FAS 142 (Goodwill) and FAS 144 (Impairment of Long-Lived Assets). Goodwill is no longer amortized but subject to annual impairment reviews. Transitional impairment tests are ongoing.
Investor Verification Checklist
- Covenant Compliance: Verify BASi's ability to maintain required financial ratios (EBITDA to debt, current ratio) given the recent increase in debt and negative operating cash flow.
- PKLB Merger Status: Confirm the timeline and funding requirements for the PharmaKinetics merger, specifically the reliance on the sale of the Baltimore property.
- Accounts Receivable: Investigate the $551k increase in accounts receivable and its impact on future cash collections.
- Construction Costs: Monitor the total cost and completion dates for the Evansville and West Lafayette facility expansions ($3.5M and $4.0M respectively).
- Goodwill Impairment: Review the results of the transitional goodwill impairment tests required by FAS 142, due by March 31, 2003.